T2Candida Panel

Faster targeted therapy and reduction in empiric antifungal costs

The T2Candida® Panel is the first and only FDA-cleared and CE-marked direct-from-blood fungal pathogen detection assay, providing same-day results directly from a whole blood specimen for the most clinically relevant fungi.

T2Candida’s greatest clinical utility is for patients in any of these conditions1:

  • Admitted to the ICU
  • Have febrile neutropenia
  • Have septic shock
  • Have an LVAD and evidence of active infection
  • In ICU at high risk for candidemia

Reduction in mortality rates: Candida infections have an overall mortality rate of 40%, but if patients receive targeted treatment within 12 hours, the mortality rate can be reduced to 11%.2,3 T2Candida provides a clear and compelling solution, with results in just hours without waiting for slow-growing fungal infections, which are often mistaken as bacterial infections, to reach positivity.

Unprecedented speed and accuracy: The T2Candida Panel pivotal clinical trial demonstrated results in 3 to 5 hours.4 All other FDA-cleared Candida diagnostic methods require a positive blood culture. Blood culture misses up to half of infections and often will take 2 to 8 days to become positive.Only then can identification be performed. In most cases, a negative result is not confirmed for 5 days after collection and processing of the blood culture.

Faster targeted therapy: Faster time to appropriate therapy has been consistently demonstrated to reduce overall length of stay in the hospital and ICU and results in a savings of $30,000 per patient.6 See how Henry Ford in Michigan and Lee Health in Florida have demonstrated faster targeted therapy for patients in clinical care for more than 24 hours.7,8

Watch T2Candida at work.

Contact us to request a demo of the T2Candida Panel!

……………………………………….

1. Clancy CJ and Nguyen MH. Diagnostic Microbiology and Infectious Disease, 2018
2. Morrell M, et al. Antimicrobial Agents and Chemotherapy, 2005
3. Garey KW, et al.  Clinical Infectious Diseases, 2006
4. Mylonakis E, et al. Clinical Infectious Diseases, 2015
5. Clancy CJ and Nguyen MH. Clinical Infectious Diseases, 2013
6. Arnold HM, et al. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
7. Wilson NM, et al. The Journal of Antimicrobial Stewardship, 2017